CVRx Inc. 2026年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule12b-2 of the Exchange Act. TABLE OF CONTENTS PartIFinancial Information Table of Contents CVRx,Inc.Quarterly Report on Form10-QFor the quarterly period ended March 31, 2026 Cautionary Noteon Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning ofthe Private Securities Litigation Reform Act of 1995. We intend such forward-looking statementsto be covered by the safe harbor provisions for forward-looking statements contained in Section27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of theSecurities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or othersimilar expressions, although not all forward-looking statements contain these words. Theforward-looking statements in this Quarterly Report on Form 10-Q are only predictions and arebased largely on our current expectations and projections about future events and financialtrends that we believe may affect our business, financial condition, and results of operations.These forward-looking statements speak only as of the date of this Quarterly Report on Form 10- You should read this Quarterly Report on Form 10-Q and the documents that we reference in thisQuarterly Report on Form 10-Q completely and with the understanding that our actual futureresults may be materially different from what we expect. We qualify all of our forward-lookingstatements by these cautionary statements. Except as required by applicable law, we do not planto publicly update or revise any forward-looking statements contained herein, whether as a result Our business is subject to numerous risks and uncertainties, including those described in Part I,Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31,2025, as updated in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You ●we have a history of significant losses, which we expect to continue, and we maynot be able to achieve or sustain profitability;●our principal stockholders, management, and directors (one of whom is affiliatedwith one of our principal stockholders) own a significant percentage of our stockand will be able to exert significant control over matters subject to stockholder ●we have limited commercial sales experience marketing and selling Barostim, andif we are unable to continue to maintain and grow sales and marketing capabilities,we will be unable to generate sustained and increasing product revenue;●we must continue to demonstrate to physicians and patients the merits of Barostim;●if third-party payers do not provide adequate coverage and reimbursement for theuse of Barostim, our revenue will be negatively impacted;●our industry is highly competitive; if our competitors, many of which are large, well-established companies with substantially greater resources than us and have along history of competing in the heart failure market, are better able to develop andmarket products that are safer, more effective, less costly, easier to use, orotherwise more attractive than Barostim, our business will be adversely impacted;●if we fail to receive access to hospitals, our sales may decrease;●we are dependent upon third-party manufacturers and suppliers, and in somecases a limited number of suppliers, making us vulnerable to supply shortages, lossor degradation in performance of the suppliers, price fluctuations, and ongoingsupply chain disruptions, which could harm our business; ●manufacturing risks may adversely affect our ability to manufacture our product andcould reduce our gross margin and profitability; ●our clinical studies may not produce results necessary to support regulatoryclearance or approval, and could produce negative or inconclusive results; ●a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwidecould adversely affect our business; ●we may face product liability claims that could be costly, divert management’sattention and harm our reputation; ●we may in the futur